Received Jan 31, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | N/A | 5N9L9 | RA |
On 01/31/2026, a 15-year-old patient presented with an external immunization record/vaccine sheet. The document contained small and difficult-to-read text, which led to a misinterpretation of the vaccine requirement. As a result, a Tdap vaccine was administered instead of the intended Polio (IPV) vaccine. Upon review of the patient's immunization history after administration, it was identified that the patient had previously received a Tdap vaccine on 01/09/2026, making the Tdap dose administered on 01/31/2026 an extra dose given below the minimum recommended interval according to national immunization guidelines. The error was identified promptly following vaccine administration. The patient and parent/guardian were informed immediately and transparently about the error. The patient was monitored on site according to standard post-vaccination observation protocols. During the observation period, the patient remained asymptomatic, with no adverse reactions or symptoms observed. Vital signs remained stable, and the patient tolerated the vaccine without complications. The patient and parent/guardian were advised that the additional Tdap dose does not pose a safety concern but does not count toward series completion due to minimum interval requirements. It was explained that the Polio (IPV) vaccine remains due and will be administered at a future visit in accordance with immunization guidelines. The patient and parent/guardian were instructed to monitor for any delayed symptoms and to seek medical attention if concerns arise.